Bone Biologics Corp Warrants
BBLGW
5 hedge funds and large institutions have $42K invested in Bone Biologics Corp Warrants in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
32% less capital invested
Capital invested by funds: $62K → $42K (-$20K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.86K |
BBLGW Hedge Fund Activity: Q3 2022 in Review
5 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q3 2022, worth a combined $42K — down 32% from $62K a quarter earlier.
Fund positioning in BBLGW was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Warberg Asset Management, cutting an estimated $1.86K.
- 5 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $42K of Bone Biologics Corp Warrants stock for Q3 2022, down 32% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q3 2022 and 0 closed out.
- The largest Bone Biologics Corp Warrants seller in Q3 2022 was Warberg Asset Management, an estimated $1.86K sold.
Based on aggregated 13F filings for Q3 2022.